| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5148 | Tiemonium Iodide | Muscarinic receptor antagonist, anticholinergic,and parasympatholytic |
|
| DCC5149 | Tigilanol Tiglate | Natural anticancer agent fortreatment of mast cell tumor (MCT) |
|
| DCC5150 | Tillman Reagent | Widely used oxidation-reduction indicator |
|
| DCC5151 | Tilmicosin Phosphate | Macrolide antibiotic for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia (Pasteurella) haemolytica |
|
| DCC5152 | Tilorone Dihydrochloride | Antiviral, antineoplastic, and anti-inflammatory agent; Orally active interferon inducer, inhibiting Ebola virus (EBOV) |
|
| DCC5153 | Tinostamustine Hydrochloride | Novel pan-histone-deacetylase inhibitor with alkylating activity |
|
| DCC5154 | Tinyatoxin | Neurotoxin, acting via vanilloid receptors of sensory nerves |
|
| DCC5155 | Tioxolone | Novel hepcidin antagonist |
|
| DCC5156 | tipp-204 | hPPAR |
|
| DCC5157 | tipp-401 | Dual PPA |
|
| DCC5158 | tipp-703 | hPPAR-pan agonist |
|
| DCC5159 | Tiracizine Hydrochloride | Anti-arrhythmia agent |
|
| DCC5160 | Tl13-117 | Novel AC220-based FLT3 degrader |
|
| DCC5161 | Tl13-149 | Novel AC220-based FLT3 degrader |
|
| DCC5162 | Tli3-12 | The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
| DCC5163 | Tli3-i12 | The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
| DCC5164 | Tlk19781 | Novel Insulin Receptor Modulator |
|
| DCC5165 | tlr4-in-c35 | Novel Toll-Like Receptor 4 (TLR4) Inhibitor |
|
| DCC5166 | Tlr7/8-in-cmpd2 | Novel potent and selective dual TLR7/8 inhibitor |
|
| DCC5167 | Tlr8-in-5 | Novel toll-like receptor 8 (TLR8) inhibitor, potently and selectively reducing TLR8-mediated signaling |
|
| DCC5168 | Tls-in-5 | The first small molecule inhibitor of translesion synthesis (TLS) that target Rev1-CT |
|
| DCC5169 | Tm2-119 | Potent histone methyltransferase inhibitor with rapid antimalarial activity against all blood stage forms in Plasmodium falciparum |
|
| DCC5170 | Tm-233 | Novel inhibitor of both JAK/STAT and proteasome activities, inducing cell death in myeloma cells |
|
| DCC5171 | Tm5001 | Novel inhibitor of plasminogen activator inhibitor-1 (PAI-1) |
|
| DCC5172 | Tma-230 | Penem beta-lactam antibiotic |
|
| DCC5173 | Tmc-310911 | Novel protease inhibitor (PI) against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, also showing antiviral avtivity as a potential treatment for COVID-19 caused by SARS-CoV-2 |
|
| DCC5174 | Tm-p4-thal | Dual Inhibitor of SIRT2 Deacetylase and Defatty-Acylase Activities |
|
| DCC5175 | Tmp-b3a | Novel degrader of E. coli DHFR (eDHFR), as well as eDHFR-EGFP fusion proteins, demonstrating that degradation does not require covalent attachment of the tag to the target protein |
|
| DCC5176 | Tmp-nvoc-halo | Novel caged protein labeling agent |
|
| DCC5177 | Tmppaa | Allosteric agonist and positive allosteric modulator (PAM) of 5-HT3 receptor |
|
